What do systematic reviews say?

Any glucocorticoid vs placebo

Glucocorticoid showed no clear difference in all‐cause mortality at longest compared with placebo (moderate certainty).

• Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass 2020 · Cochrane Headline outcomes only
  RR 0.83 [0.33, 2.07]
  5 studies · 313 participants
  Moderate

Any glucocorticoid vs placebo

Glucocorticoid showed no clear difference in cardiovascular mortality at longest compared with placebo (moderate certainty).

• Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass 2020 · Cochrane Headline outcomes only
  RR 0.4 [0.07, 2.46]
  3 studies · 109 participants
  Moderate

Any glucocorticoid vs placebo

Glucocorticoid showed no clear difference in failure to separate from CPB compared with placebo (low certainty).

• Prophylactic corticosteroids for paediatric heart surgery with cardiopulmonary bypass 2020 · Cochrane Headline outcomes only
  RR 0.2 [0.01, 3.92]
  1 study · 40 participants
  Low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  This outcome was not reported in either of the trials.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  No randomised or quasi-randomised controlled trials in people with Von Willebrand disease met the inclusion criteria; no eligible VWD trials were identified.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Only reported in the Walsh (EACA) trial: in none of the 31 included participants was blood transfusion required.
  1 study · 31 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Mean fall in haemoglobin. Forbes (TXA): 1.4 g/100 mL (placebo) vs 0.3 g/100 mL (TXA). Walsh (EACA): 6.3% (placebo, both centres) vs 3.9% and 3.7% (EACA, centres 1 and 2); differences not significant. Reported in…
  2 studies · 59 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  This outcome was not reported in either of the trials.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Reported in both trials in different ways. Forbes (TXA): mean units of replacement therapy per root extracted 617 IU (range 0 to 15,800) in 11 placebo participants versus 30 IU and 65 IU per root in 2 TXA participants…
  2 studies · 59 participants
  GRADE not reported

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

The review found no eligible studies for this question.

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  This outcome was not reported in either of the trials.
  0 studies
  No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… probably leads to lower number of postoperative bleeding episodes requiring intervention compared with placebo, no intervention or usual care (with or without placebo) (moderate certainty).

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes

  Up to 10 days postoperative
  RD -0.57 [-0.76, -0.37]
  2 studies · 59 participants
  Moderate

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
  Only reported in the Forbes (TXA) trial: over five-day follow-up, mean blood loss per participant 84.1 mL (range 4 to 323) in the placebo group (n=14) versus 61.2 mL (range 1 to 749) in the TXA group (n=14), P = 0.02.
  1 study · 28 participants
  GRADE not reported

Intervention not reported

• Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 1156 participants
  Low

Intervention not reported

• Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 190 participants
  Low

Intervention not reported

• Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 1075 participants
  Low

Intervention not reported

• Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 271 participants
  Very low

Intervention not reported

• Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 396 participants
  Very low

Intervention not reported

• Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 235 participants
  Low

Intervention not reported

• Early enteral nutrition within 24 hours of lower gastrointestinal surgery versus later commencement for length of… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 235 participants
  Low

Intervention not reported

The intervention probably leads to lower all VTE (moderate certainty).

• Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery 2019 · Cochrane Headline outcomes only
  OR 0.38 [0.26, 0.54]
  7 studies · 1728 participants
  Moderate